C07K 2317/60
Characterized by non-natural combinations of immunoglobulin fragments
Official title: characterized by non-natural combinations of immunoglobulin fragments
C07K2317/60 (Characterized by non-natural combinations of immunoglobulin fragments) appears on 6,862 US grants and 14,051 published applications in this corpus.
Search patents in C07K- Granted patents
- 6,862
- Published applications
- 14,051
- Assignees
- 3,284
- Inventors
- 19,104
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 5 | 0 |
| 1997 | 11 | 0 |
| 1998 | 21 | 0 |
| 1999 | 43 | 0 |
| 2000 | 38 | 0 |
| 2001 | 33 | 10 |
| 2002 | 45 | 79 |
| 2003 | 43 | 157 |
| 2004 | 26 | 140 |
| 2005 | 32 | 196 |
| 2006 | 52 | 179 |
| 2007 | 56 | 137 |
| 2008 | 65 | 168 |
| 2009 | 98 | 209 |
| 2010 | 109 | 240 |
| 2011 | 118 | 269 |
| 2012 | 156 | 257 |
| 2013 | 155 | 331 |
| 2014 | 180 | 394 |
| 2015 | 253 | 440 |
| 2016 | 319 | 612 |
| 2017 | 331 | 681 |
| 2018 | 353 | 722 |
| 2019 | 419 | 816 |
| 2020 | 517 | 979 |
| 2021 | 532 | 1150 |
| 2022 | 543 | 1207 |
| 2023 | 519 | 1236 |
| 2024 | 649 | 1392 |
| 2025 | 679 | 1167 |
| 2026 | 452 | 883 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Cell-receptor targeted exosomes6 Oct 2026US 12,751,930 B2City of Hope
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308231 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308232 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308233 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Production of chimeric antibodies - a combinatorial approach1,367US 5,565,332 ACambridge Antibody Technology Limited · 1996
- Humanised antibodies1,093US 5,859,205 ACelltech Limited · 1999
- Methods for producing members of specific binding pairs893US 5,969,108 ACambridge Antibody Technology Limited · 1999
- Methods for in vitro recombination882US 5,605,793 AAffymax Technologies N.V. · 1997
- Methods for producing members of specific binding pairs849US 5,733,743 ACambridge Antibody Technology Limited · 1998